NEW YORK – Fluidigm said on Wednesday that it will exclusively distribute antibodies from Bethyl Laboratories for use with Fluidigm's Imaging Mass Cytometry technology.
Bethyl Laboratories has a portfolio of more than 9,500 primary and secondary antibodies, including the recombinant monoclonal antibodies that are well-suited for imaging studies. Under the new agreement, antibody products manufactured by Bethyl will be verified on Fluidigm's Hyperion imaging system and subsequently offered to Fluidigm's customers.